Basit öğe kaydını göster

dc.contributor.authorBilge, Sule Yasar
dc.contributor.authorSolmaz, Dilek
dc.contributor.authorSenel, Soner
dc.contributor.authorEmmungil, Hakan
dc.contributor.authorKilic, Levent
dc.contributor.authorOner, Sibel Yilmaz
dc.contributor.authorYidiz, Fatih
dc.contributor.authorYilmaz, Sedat
dc.contributor.authorBozkirli, Duygu Ersozlu
dc.contributor.authorTufan, Muge Aydin
dc.contributor.authorYilmaz, Sema
dc.contributor.authorYazisiz, Veli
dc.contributor.authorPehlivan, Yavuz
dc.contributor.authorBes, Cemal
dc.contributor.authorCetin, Gozde Yildirim
dc.contributor.authorErten, Sukran
dc.contributor.authorGonullu, Emel
dc.contributor.authorSahin, Fezan
dc.contributor.authorAkar, Servet
dc.contributor.authorAksu, Kenan
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorDireskeneli, Haner
dc.contributor.authorErken, Eren
dc.contributor.authorKisacik, Bunyamin
dc.contributor.authorSayarlioglu, Mehmet
dc.contributor.authorCinar, Muhammed
dc.contributor.authorKasifoglu, Timucin
dc.contributor.authorSari, Ismail
dc.date.accessioned2021-06-03T05:20:18Z
dc.date.available2021-06-03T05:20:18Z
dc.date.issued2019
dc.identifier.issn2147-9720
dc.identifier.urihttp://dx.doi.org/10.5152/eurjrheum.2018.18115
dc.identifier.urihttp://hdl.handle.net/11655/24024
dc.description.abstractObjective: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Most of the identified disease-causing mutations are located on exon 10. As the number of studies about the effect of the exonal location of the mutation and its phenotypic expression is limited, we aimed to investigate whether the exonic location of the Mediterranean fever (MEFV) mutation has an effect on the clinical manifestation in patients with FMF. Methods: Study population was derived from the main FMF registry that included 2246 patients from 15 different rheumatology clinics. We categorized the mutations according to their exon locations and retrieved the clinical and demographic information from the database. Results: Patients having the MEFV mutations on exon 2 or 10 (n: 1526) were divided into three subgroups according to the location of the MEFV mutations: Group 1 (exon 2 mutations), Group 2 (exon 10 mutations), and Group 3 (both exon 2 and exon 10 mutations). Group 2 patients were of a significantly younger age at onset, and erysipel-like erythema, arthritis, amyloidosis, and a family history of FMF were more common in this group. Conclusion: Patients with FMF and exon 10 mutations show more severe clinical symptoms and outcome. Exon 2 mutations tend to have a better outcome.
dc.language.isoen
dc.relation.isversionof10.5152/eurjrheum.2018.18115
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectM694V
dc.subjectE148Q
dc.subjectexon 10
dc.subjectexon 2
dc.subjectfamilial Mediterranean fever
dc.titleExon 2: Is It The Good Police In Familial Mediterranean Fever?
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalEuropean Journal Of Rheumatology
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume6
dc.identifier.issue1
dc.description.indexWoS
dc.description.indexPubMed


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

Attribution 4.0 United States
Aksi belirtilmediği sürece bu öğenin lisansı: Attribution 4.0 United States